BINGTAO LIN: Open Payments
NPI 1407277155 · ROSEVILLE, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$675 in 16 payments from 9 companies in 2025. Trend: 2023 $1,697 · 2024 $760 · 2025 $675
Food & beverage: $675
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 4 | $182 |
| Novo Nordisk Inc | 2 | $140 |
| Abbott Laboratories | 1 | $114 |
| Bayer Healthcare Pharmaceuticals Inc. | 3 | $101 |
| VERTEX PHARMACEUTICALS INCORPORATED | 2 | $51 |
| Lilly USA, LLC | 1 | $26 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 1 | $24 |
| Ardelyx, Inc. | 1 | $21 |
| Cranial Technologies, Inc | 1 | $15 |
Products named: UBRELVY, Ozempic, PROCLAIM, Kerendia, JOURNAVX, MOUNJARO, RELISTOR, LINZESS.
Industry payments across CA — which companies pay providers there.
